ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,011.12
-0.22%
US Tech 100
16,824.00
-0.66%
Dow Jones
37,775.38
0.06%
Brent Oil
86.085
-0.38%
Bitcoin
64,644.97
1.79%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Stoke Therapeutics Inc (STOK) Quote

Stoke Therapeutics Inc

Stoke Therapeutics Inc (STOK)

NASDAQ
11.65
-0.07
(-0.60%)
Closed April 18 4:00PM
Delayed by 15 minutes
11.65
0.00
( 0.00% )
Pre Market: 4:00AM
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
11.65
Bid
11.20
Ask
16.00
Volume
1
0.00 Day's Range 0.00
3.35 52 Week Range 16.3999
Market Cap
520.217M
Previous Close
11.65
Open
-
Last Trade
1
@
11.34
Last Trade Time
05:29:45
Financial Volume
-
VWAP
-
Average Volume (3m)
1,208,187
Shares Outstanding
44,653,782
Dividend Yield
-
PE Ratio
-4.97
Earnings Per Share (EPS)
-2.34
Revenue
8.78M
Net Profit
-104.7M

About Stoke Therapeutics Inc

Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively... Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.stoketherapeutics.com
Headquarters
Dover, Delaware, USA
Founded
1970
Stoke Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker STOK. The last closing price for Stoke Therapeutics was $11.65. Over the last year, Stoke Therapeutics shares have traded in a share price range of $ 3.35 to $ 16.3999.

Stoke Therapeutics currently has 44,653,782 shares outstanding. The market capitalization of Stoke Therapeutics is $520.22 million. Stoke Therapeutics has a price to earnings ratio (PE ratio) of -4.97.

STOK Latest News

More News

Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer

– Mr. Hoitt brings more than two decades of successful commercial experience with an emphasis on rare diseases – Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to...

April 17 2024
Business Wire

Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today...

April 04 2024
Business Wire

Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today...

March 27 2024
Business Wire

Stoke Therapeutics Announces Proposed Public Offering

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today...

March 26 2024
Business Wire

Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome

– Phase 1/2a End of Study Data: 70mg doses demonstrated substantial and sustained reductions in convulsive seizure frequency on top of the best available anti-seizure medicines; Median reductions...

March 25 2024
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

March 05 2024
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

March 01 2024
Edgar (US Regulatory)

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

February 26 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1.7-12.73408239713.3513.8211.54109244212.06474022CS
45.6493.843594016.0116.39995.93321124312.04441174CS
126.77138.7295081974.8816.39994.09120818711.31966788CS
267.86207.3878627973.7916.39993.3567189410.21890126CS
523.0435.30778164928.6116.39993.355026499.42471964CS
156-19.41-62.491951062531.0641.63.3533644013.40300161CS
260-15.56-57.184858507927.2171.583.3527000617.81453985CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
RWODRedwoods Acquisition Corporation
$ 21.09
(163.74%)
600.38k
ZCMDZhongchao Inc
$ 2.52
(73.79%)
2.27M
PEGRProject Energy Reimagined Acquisition Corporation
$ 13.12
(42.76%)
72.74k
SUGPSU Group Holdings Ltd
$ 2.51
(35.68%)
8.4k
WLGSWang and Lee Group Inc
$ 0.6699
(33.98%)
391.08k
MBOTMicrobot Medical Inc
$ 0.36
(-59.55%)
24
BGLCBioNexus Gene Lab Corporation
$ 0.6349
(-25.18%)
31.41k
TIRXTian Ruixiang Holdings Ltd
$ 0.6295
(-21.31%)
172.82k
SPECSpectaire Holdings Inc
$ 0.4905
(-20.89%)
67.45k
BTCYBiotricity Inc
$ 1.20
(-18.92%)
1.06k
HUBCHub Cyber Security Ltd
$ 1.55
(20.16%)
2.49M
SQQQProShares UltraPro Short QQQ
$ 12.31
(1.99%)
2.38M
ZCMDZhongchao Inc
$ 2.52
(73.79%)
2.27M
SINTSiNtx Technologies Inc
$ 0.0378
(-5.50%)
1.56M
SPCBSuperCom Ltd
$ 0.292
(21.67%)
1.37M

STOK Discussion

View Posts
Zardiw Zardiw 3 weeks ago
$STOK Chart from #DDAmanda - #1 Stock Screener :

Scans are preset. Push a Button. Find Winners Early:



Z
👍️0
TimeFades TimeFades 3 weeks ago
Choppy day shoulda just stuck with my morning short
👍️0
TimeFades TimeFades 3 weeks ago
Got bullish again and covered
👍️0
TimeFades TimeFades 3 weeks ago
Short from 12s
👍️0
Invest-in-America Invest-in-America 3 weeks ago
STOK: "Stoke Therapeutics (NASDAQ:STOK) stock shot up 70% in post-market trading Monday after the company reported positive results from studies for its drug STK-001 in the treatment of children and adolescents with Dravet syndrome, a genetic form of epilepsy. The biotech company said data from two Phase 1/2a studies and two open label extension, or OLE, studies showed “clinically meaningful effects” that included “substantial and durable reductions in convulsive seizure frequency."
https://seekingalpha.com/news/4083468-stoke-stock-soars-post-market-on-epilepsy-drug-data

Dravet Syndrome is an extremely RARE disease in the USA. And the above news does NOT specify nor suggest that STOK's (potential) treatment for Dravet Syndrome will or might have any applications for treatment of EPILEPSY at all. (Be very CAREFUL about news like the above.)
👍️0

Your Recent History

NASDAQ
STOK
Stoke Therapeutics
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved